Policies & Legislation

Canada’s British Columbia to switch patients to biosimilars

Home/Policies & Legislation | Posted 21/06/2019

British Columbia has become the first Canadian province to stop coverage of originator biologicals and switch patients to biosimilars for certain indications.

Bulgaria and Cyprus added to EU-US mutual recognition agreement

Home/Policies & Legislation | Posted 14/06/2019

The European Medicines Agency (EMA) announced on 29 April 2019 that the mutual recognition agreement (MRA) between the European Union (EU) and the US had been extended to include two additional EU Member States, Bulgaria and Cyprus.

US considering eight years protection for biologicals in China

Home/Policies & Legislation | Posted 07/06/2019

Makers of copy biologicals in China may be set to get a further boost, as the Trump administration is said to be considering conceding to China’s proposal to shorten the period of protection granted to US drugmakers’ biologicals in the country.

FDA’s Orange and Purple Books to be improved and updated

Home/Policies & Legislation | Posted 31/05/2019

On 8 May 2019, the US House of Representatives unanimously passed two bills that aim to enhance the utility of the US Food and Drug Administration’s (FDA) Orange Book for generics makers and the Purple Book for biosimilars makers.

New biosimilar guide for pharmacists in Australia

Home/Policies & Legislation | Posted 24/05/2019

During the Generic and Biosimilar Medicines Association’s (GBMA) Biosimilar Week, Federal Minister for Health, Greg Hunt, introduced Biosimilar Week 2019 along with the launch of the Biosimilar Hub, which included a set of specific guidelines geared towards pharmacists.

Automatic pharmacist substitution of biosimilars in Germany

Home/Policies & Legislation | Posted 10/05/2019

Pharmacists in Germany may soon be able to carry out automatic substitution of biosimilars in the country.

Australia’s TGA considering whether to publish drugs under evaluation

Home/Policies & Legislation | Posted 03/05/2019

Australia’s regulatory agency, the Therapeutic Goods Agency (TGA) is consulting on whether it should publish that a prescription medicine is under evaluation.

Health Canada announces naming convention for biologicals

Home/Policies & Legislation | Posted 26/04/2019

Following a number of stakeholder consultations including the 2018 Consultation on the Naming of Biologic Drugs [1], Health Canada has decided that biological drugs, including biosimilars, will be identified by their unique brand name and non-proprietary (common) name, without the addition of a product-specific suffix. Under this naming convention, both the brand name and non-proprietary name should be used throughout the medication use process so that biologicals that share the same non-proprietary name can be distinguished by their unique brand names.

Online consultation on biological drug naming in Canada

Home/Policies & Legislation | Posted 19/04/2019

Health Canada and the Institute for Safe Medication Practices Canada conducted an online consultation on the naming of biological drugs in 2018.

US government advances five bills to increase generics competition

Home/Policies & Legislation | Posted 12/04/2019

The US House Energy & Commerce Committee’s Health Subcommittee has advanced five bills related to generic drug competition. The bills have not yet been passed but will each be considered by the full committee.